Neurodegeneration in familial amyloid polyneuropathy: from pathology to molecular signaling.
Familial amyloid polyneuropathy (FAP) is an autosomal dominant neurodegenerative disorder related to the systemic deposition of mutated transthyretin (TTR) amyloid fibrils, particularly in peripheral nervous system (PNS). TTR fibrils are diffusely distributed in the PNS of FAP patients, involving nerve trunks, plexuses and ganglia. In peripheral nerves, amyloid deposits are prominent in the endoneurium, near blood vessels, Schwann cells and collagen fibrils. Fiber degeneration is axonal, beginning in the unmyelinated and low diameter myelinated fibers. Several hypotheses have been raised to explain axonal and neuronal loss: (i) compression of the nervous tissue by amyloid; however, a cause-effect relationship between amyloid deposition, structural nerve changes and degeneration was never clearly made; (ii) role of nerve ischemia secondary to lesions caused by perivascular amyloid, which is also doubtful as compromised blood flow was never demonstrated; (iii) lesions in the dorsal root ganglia neurons or Schwann cells. Recently, evidence for the presence of toxic non-fibrillar TTR aggregates early in FAP nerves constituted a first step to unravel molecular signaling related to neurodegeneration in FAP. The toxic nature of TTR non-fibrillar aggregates, and not mature TTR fibrils, was evidenced by their ability to induce the expression of oxidative stress and inflammation-related molecules in neuronal cells, driving them into apoptotic pathways. How these TTR aggregates exert their effects is debatable; interaction with cellular receptors, namely, the receptor for advanced glycation endproducts (RAGE), is a probable candidate mechanism. The pathology and the yet unknown molecular signaling mechanisms responsible for neurodegeneration in FAP are discussed.
Sousa
Mónica Mendes
MM
Molecular Neurobiology, Instituto de Biologia Molecular e Celular, Porto, Portugal.
Saraiva
Maria João
MJ
D000682:Amyloid / Q000378:metabolism; D028227:Amyloid Neuropathies, Familial / Q000209:etiology / Q000235:genetics / Q000473:pathology*; D000818:Animals; D001369:Axons / Q000378:metabolism; D006801:Humans; D008959:Models, Neurological; D009410:Nerve Degeneration / Q000150:complications / Q000235:genetics / Q000473:pathology*; D018384:Oxidative Stress / Q000502:physiology; D010525:Peripheral Nerves / Q000166:cytology / Q000378:metabolism / Q000473:pathology; D011228:Prealbumin / Q000235:genetics / Q000378:metabolism; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic / Q000378:metabolism; D012583:Schwann Cells / Q000378:metabolism; D015398:Signal Transduction / Q000235:genetics* / Q000502:physiology
D000682:Amyloid; D011228:Prealbumin; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic